Mainz Biomed's 2026 roadmap for eAArly DETECT 2 and the ReconAAsense pivotal trial gives concrete milestones for its US colorectal cancer screening path.
MYNZ — WATCH The author argues that Mainz Biomed's update gives it a concrete clinical timeline, with the 2,000-patient eAArly DETECT 2 feasibility study underway and completion guided for the first half of 2026. Since U.S. reimbursement already exists for approved noninvasive CRC screens, the investment case hinges on clinical and operational proof rather than creating a new reimbursement code. The sequential milestones—feasibility completion followed by the ReconAAsense pivotal trial start in 2026—are the catalysts the author is watching.
Management guided that completion is expected in the first half of 2026, with ReconAAsense, the U.S. FDA pivotal CRC study, slated to begin in 2026 after feasibility wraps.
This Reddit post, published January 05, 2026, features u/sqlearner discussing MYNZ. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/sqlearner · Tickers: MYNZ